The Food and Drug Administration on Monday approved giredestrant, sold as Wilserdly, for use with everolimus to treat adults with certain advanced breast cancers that have returned or grown after hormone-based treatment. A test for a change in a tumor gene called ESR1 helps determine who qualifies.
The FDA approval covers cancers that are estrogen receptor-positive and HER2-negative, with an ESR1 mutation detected by an authorized test. The cancer must be locally advanced or metastatic. The approval applies when disease returns during or after endocrine therapy given to reduce the risk of recurrence, or progresses after at least one endocrine-based regimen for metastatic disease. For someone considering the combination, the tumor’s test results and prior treatment both matter.
What the blood test checks

The FDA also authorized a blood test called FoundationOne Liquid CDx to help identify patients for this combination. It looks for certain ESR1 mutations in pieces of tumor DNA in the blood. ESR1 is the gene that codes for the estrogen receptor. Giredestrant targets that receptor. Everolimus, a drug used in both groups in the study, targets a separate pathway involved in cell growth.
The trial enrolled 373 adults with estrogen receptor-positive, HER2-negative advanced breast cancer. Of those, 207 had the ESR1 mutations specified in the analysis. All the participants received everolimus. Researchers randomly assigned them to add giredestrant or one of three endocrine treatments selected by their doctor: exemestane, fulvestrant or tamoxifen.
What the trial found
Among participants with an ESR1 mutation, the median time before their cancer worsened or they died was 10 months with giredestrant and everolimus, compared with 5.5 months with the other endocrine treatment and everolimus. The FDA said the study had too little follow-up on deaths at that point to determine whether participants lived longer overall. Dana-Farber Cancer Institute, whose researchers led the trial, reported a median follow-up of 18.6 months for the analysis.
Common side effects with the new combination included mouth inflammation, rash, fatigue, diarrhea, muscle or joint pain, lung inflammation and nausea. The prescribing information for Wilserdly warns about a slow heart rate and harm to a fetus. An oncology team can review those risks alongside other conditions and medications when considering the treatment.






